Oramed Pharmaceuticals (ORMP) EBITDA Margin (2016 - 2025)

Oramed Pharmaceuticals' EBITDA Margin history runs 8 years deep, the most recent figure standing at 225.0% for Q1 2025.

• Quarterly EBITDA Margin changed N/A year-over-year to 225.0% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 754.4% (changed N/A YoY) and the FY2025 annual result came in at 754.4%, changed N/A from the prior year.
• EBITDA Margin was 225.0% for Q1 2025 at Oramed Pharmaceuticals, up from 562.46% in the prior quarter.
• Across five years, EBITDA Margin topped out at 225.0% in Q1 2025 and bottomed at 1693.92% in Q2 2022.
• A 4-year average of 1051.65% and a median of 1048.44% in 2021 frame the typical range for EBITDA Margin.
• Peak annual rise in EBITDA Margin reached 113145 bps in 2023, while the deepest fall reached 90751 bps in 2023.
• Oramed Pharmaceuticals' EBITDA Margin stood at 896.15% in 2021, then plunged by 52 bps to 1363.5% in 2022, then surged by 59 bps to 562.46% in 2023, then surged by 60 bps to 225.0% in 2025.
• Business Quant data shows ORMP's EBITDA Margin at 225.0% in Q1 2025, 562.46% in Q2 2023, and 781.98% in Q1 2023.